- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer
- Longer term follow-up from global pivotal clinical trials ELIANA and JULIET to be presented at ASH, reporting clinical impact of Kymriah® in patients with r/r pediatric B-cell ALL and adult DLBCL
- First data presentation for asciminib (ABL001), a chronic myeloid leukemia compound evaluated in patients who are resistant to nearly all targeted CML therapies
- New post-hoc analysis of SUSTAIN study of crizanlizumab (SEG101) evaluating the impact of treatment in vaso-occlusive crises in patients with sickle cell disease
PR Newswire
EAST HANOVER, N.J., Nov. 2, 2018